Main Menu
Main Menu

Commentary

Vietnam Appoints Army General Luong Cuong as New President

Commentary /

On October 21, Vietnam’s National Assembly unanimously elected General Luong Cuong as the country’s new president. General Secretary To Lam, who had been serving concurrently as president, will now focus on his primary role as head of the Communist Party. Luong Cuong’s promotion signifies Vietnam’s return to the tradition of collective leadership, with power shared among the four highest ranking positions (the “four pillars”) – general secretary, president, prime minister, and chairman of the national assembly. With a decades-long career in the military, Luong Cuong adds a military presence to Vietnam’s leadership group, which was dominated by those with a police background.

Vietnam Appoints Army General Luong Cuong as New President Read More »

Harris vs. Trump Indo-Pacific Policies Summary

Commentary /

Key Takeaways Trade and Investment: Harris and Trump both aim to protect U.S. domestic industry and constrain China’s technological advancement, but Trump is much more enthusiastic about applying new tariffs on China. Regarding technology denial, Trump would try to accrue negotiating leverage through transactional, unilateral, and entity-based approaches to controls on exports and foreign investment.

Harris vs. Trump Indo-Pacific Policies Summary Read More »

Japan’s Drug Innovation Incentive Policies: Policy Challenges Undermine Desired Goals (ENG)

Commentary /

The Asia Group (TAG) has released an update to its 2023 white paper “Observations on Drug Pricing and Innovation in Japan” which analyzes the outstanding policy challenge of the “zero co-factor” rule under the cost-based price calculation method, which continues to undermine the Japanese government’s efforts to restore the country’s drug discovery capabilities and create a robust pharmaceutical industry ecosystem.

Japan’s Drug Innovation Incentive Policies: Policy Challenges Undermine Desired Goals (ENG) Read More »

日本の創薬インセンティブ政策：望まれる目標の実現を困難とする政策的課題 (JPN)

Commentary /

 複雑な薬事行政環境にもかかわらず、多くの製薬会社にとり日本は依然として重要な市場である。日本市場は、2023年には約880億ドルで米国と欧州連合に次ぐ世界第3位であり、2029年には約919.4億ドルになると見込まれる。

日本の創薬インセンティブ政策：望まれる目標の実現を困難とする政策的課題 (JPN) Read More »

Prabowo Subianto Sworn In as Indonesia’s President; Announces Cabinet

Commentary /

On October 20, Prabowo Subianto was inaugurated as Indonesia’s eighth president. Outlining his administration’s priorities in his inaugural address, Prabowo emphasized his campaign pledges on improving nutrition, healthcare, and housing, while also highlighting the continuation of President Joko “Jokowi” Widodo’s industrialization policy (including through the export ban of raw critical minerals). Notably, Prabowo did not mention the development of the new capital city, Nusantara, one of Jokowi’s expensive legacy policy priorities that will likely compete with the new President’s own priorities for resources.

Prabowo Subianto Sworn In as Indonesia’s President; Announces Cabinet Read More »

Harris vs. Trump: Indo-Pacific Alliances

Commentary /

The United States has formal bilateral defense treaties with Japan, South Korea, the Philippines, Thailand, and Australia, comprising the foundation of its regional security strategy. Washington views these alliances as critical to ensuring regional stability, deterring adversaries, and promoting a “free and open Indo-Pacific” that supports economic prosperity and protects territorial sovereignty. 

Harris vs. Trump: Indo-Pacific Alliances Read More »

Prospects and Impact of De Minimis Policy Reform

Commentary /

The White House and Congress are increasingly concerned about the growing number of Chinese goods that bypass import duties. In 2016, Congress raised the import value threshold under de minimis from USD 200 to USD 800, but by 2021, Congress reopened debate on the threshold given the explosion of China’s fast- fashion retailers and the growing fentanyl crisis in the United States.

Prospects and Impact of De Minimis Policy Reform Read More »

Scroll to Top

You Are Applying For:

Russia Becoming a Major U.S. – China Flashpoint

Apply Now

Submit the details below, and our HR team member will get in touch with you shortly.

The Asia Group is an equal opportunity employer where an applicant’s qualifications are considered without regard to race, color, religion, sex, national origin, age, disability, veteran status, genetic information, sexual orientation, gender identity or expression, or any other basis prohibited by law. The Asia Group continually seeks to diversify its staff, particularly to broaden opportunities for individuals from demographic groups that are historically underrepresented in the strategic advisory profession.

"*" indicates required fields

1Personal Details
2Questionnaire & Application Materials
3Voluntary Self Identification

Personal Details

Name*
Address*